Cambridge Investment Research Advisors Inc. lessened its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 40.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,648 shares of the company’s stock after selling 1,769 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Henry Schein were worth $225,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also bought and sold shares of the company. NEXT Financial Group Inc purchased a new position in Henry Schein in the 3rd quarter worth approximately $103,000. McAdam LLC purchased a new position in Henry Schein in the 3rd quarter worth approximately $104,000. Piedmont Investment Advisors LLC purchased a new position in Henry Schein in the 2nd quarter worth approximately $130,000. Fuller & Thaler Asset Management Inc. boosted its holdings in Henry Schein by 57.1% in the 2nd quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock worth $160,000 after acquiring an additional 800 shares during the period. Finally, Howland Capital Management LLC purchased a new position in Henry Schein in the 3rd quarter worth approximately $207,000.
A number of equities analysts have weighed in on the company. Piper Jaffray Companies restated an “overweight” rating and issued a $96.00 price target on shares of Henry Schein in a report on Thursday, November 29th. Barrington Research upped their price target on Henry Schein from $92.00 to $96.00 and gave the stock an “outperform” rating in a report on Thursday, November 8th. BidaskClub upgraded Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 1st. Edward Jones cut Henry Schein from a “hold” rating to a “sell” rating in a report on Thursday, October 25th. Finally, Goldman Sachs Group assumed coverage on Henry Schein in a report on Saturday, October 20th. They issued a “hold” rating and a $78.00 price target for the company. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Henry Schein has an average rating of “Hold” and a consensus target price of $86.47.
Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, November 6th. The company reported $1.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.01 by $0.02. The company had revenue of $3.28 billion during the quarter, compared to analysts’ expectations of $3.37 billion. Henry Schein had a return on equity of 20.40% and a net margin of 3.00%. The business’s revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.87 EPS. As a group, analysts forecast that Henry Schein, Inc. will post 4.12 earnings per share for the current year.
In other news, insider David Mckinley sold 8,321 shares of the stock in a transaction that occurred on Friday, November 30th. The stock was sold at an average price of $88.77, for a total transaction of $738,655.17. Following the completion of the transaction, the insider now directly owns 68,012 shares in the company, valued at approximately $6,037,425.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.15% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Henry Schein, Inc. (HSIC) Shares Sold by Cambridge Investment Research Advisors Inc.” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.com-unik.info/2018/12/04/henry-schein-inc-hsic-shares-sold-by-cambridge-investment-research-advisors-inc.html.
Henry Schein Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.